EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein

Tianchun Wu iD, Han Yang, Jinjin Li, Hongbo Fang, Xiaoyi Shi, Jie Li, Liushun Feng

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0299920 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tianchun Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Diterpenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical scientific and technological research joint construction projects of Henan province, 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths. However, the HCC treatment is still challenging. Herein, we aimed to reveal the anti-tumor effect of Jolkinolide B in HCC cell lines Huh-7 and SK-Hep-1. The results showed that Jolkinolide B inhibited the migration, invasion, and epithelial-to-mesenchymal transition(EMT) of HCC cells. In addition, Jolkinolide B induced HCC cell apoptosis by upregulating Bax and downregulating BCL-2 expressions. Furthermore, we demonstrated that Jolkinolide B inactivated the β-catenin signaling and reduced Musashi-2 expression. Finally, we revealed that Musashi-2 overexpression reversed the Jolkinolide B-induced anti-HCC effect. Overall, we proved that Jolkinolide B is a potential candidate for treating HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDiterpenesHumansCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticCell Proliferation

Substanzen

jolkinolide BDiterpenes

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
  • Division of Hepatobiliary and Pancreatic Surgery, Henan Key Laboratory of Digestive Organ Transplanation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.

ORCID-Profile: Tianchun Wu

Förderung

  • Medical scientific and technological research joint construction projects of Henan province, 2020

Zitieren

APA

Wu, T., Yang, H., Li, J., Fang, H., Shi, X., Li, J., & Feng, L. (2024). Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein. PLOS ONE. https://doi.org/10.1371/journal.pone.0299920

Vancouver

Wu T, Yang H, Li J, Fang H, Shi X, Li J, et al. Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein. PLOS ONE. 2024. doi:10.1371/journal.pone.0299920

BibTeX
@article{Wu2024,
  author = {Wu, Tianchun and Yang, Han and Li, Jinjin and Fang, Hongbo and Shi, Xiaoyi and Li, Jie and Feng, Liushun},
  title = {Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0299920}
}
Kostenlos starten →